Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
COYA
#3330
Coya Therapeutics, Inc. Common Stock
4.9
6
+1.22%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+1.22%
Aylık değişim
+2.06%
6 aylık değişim
-25.30%
Yıllık değişim
-24.04%
Önceki kapanış
4.9
0
Open
4.9
6
Bid
Ask
Low
4.9
6
High
4.9
6
Hacim
2
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
COYA
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Cash from operating activities
-5.46 M
-2.41 M
-2.83 M
-5.77 M
-1.13 M
-12.14 M
Cash from investing activities
0
0
-25 K
0
0
—
Cash from financing activities
-56.33 K
9.69 M
19.14 K
0
19.14 K
9.73 M
Free cash flow
-5.46 M
-2.41 M
-2.83 M
-5.77 M
-1.13 M
-12.14 M
Haberler
Coya Therapeutics: H.C. Wainwright bestätigt "Kaufen"-Rating mit 18-Dollar-Kursziel
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock with $18 target
Coya Therapeutics sichert sich 11,1 Millionen US-Dollar durch Privatplatzierung
Coya Therapeutics secures $11.1 million in private placement
Coya Therapeutics treibt klinische Studien zu ALS und FTD voran
Coya Therapeutics advances ALS and FTD clinical trials in 2026
H.C. Wainwright bestätigt Kaufempfehlung für Coya Therapeutics und sieht 218 % Kurspotenzial
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18
Tracking David Einhorn’s Greenlight Capital Portfolio – Q3 2025 Update (NYSE:GRBK)
Coya Therapeutics: H.C. Wainwright bekräftigt "Buy"-Rating und Kursziel von 18 Dollar
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock
Coya Therapeutics: H.C. Wainwright bekräftigt "Buy"-Rating und Kursziel von 18 USD